Skip to main content
SpringerLink
Log in

Selecting Patients for KIT Inhibition in Melanoma

  • Protocol
  • First Online:
Molecular Diagnostics for Melanoma

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1102))

Abstract

For many years, melanoma has been regarded as a single disease in terms of therapeutic considerations. The more recent identification of multiple molecular mechanisms underlying the development, progression, and prognosis of melanoma has led to a new paradigm for the management of this disease, has created new therapeutic opportunities, and has led to improved clinical outcomes. Such advances, however, are dependent upon methods that can reproducibly identify key molecular alterations within an individual tumor, define clinically relevant genetic subgroups of disease, and permit improved patient selection for targeted therapies.

Melanomas harboring genetic alterations of KIT have been demonstrated to constitute one such molecular subgroup of disease. In this chapter, we will discuss the biology of KIT in melanoma, review the rationale for and clinical data regarding KIT inhibition in melanomas harboring activating alterations of KIT, propose guidelines for the selection of patients for KIT inhibitor therapy, and, finally, present laboratory methods for KIT assessment in melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS et al (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17(9):2745–2751

    CAS  PubMed  Google Scholar 

  2. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K et al (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17(7):2105–2116

    CAS  PubMed  Google Scholar 

  3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949–954

    Article  CAS  PubMed  Google Scholar 

  4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516

    Article  CAS  PubMed  Google Scholar 

  5. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358–365

    Article  CAS  PubMed  Google Scholar 

  6. Robert C, Flaherty K, Hersey P, Nathan P, CGarbe C, Milhem M, et al (2012) METRIC phase III study: efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM). J Clin Oncol 30(suppl):(abstr LBA8509)

    Google Scholar 

  7. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353(20):2135–2147

    Article  CAS  PubMed  Google Scholar 

  8. Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM et al (2008) Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 49(12):5230–5234, PMCID: 2634606

    Article  PubMed  Google Scholar 

  9. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O’Brien JM et al (2009) Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457(7229):599–602, PMCID: 2696133

    Article  PubMed  Google Scholar 

  10. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T et al (2010) Mutations in GNA11 in uveal melanoma. N Engl J Med 363(23):2191–2199

    Article  PubMed  Google Scholar 

  11. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA et al (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330(6009):1410–1413

    Article  CAS  PubMed  Google Scholar 

  12. Rimoldi D, Salvi S, Lienard D, Lejeune FJ, Speiser D, Zografos L et al (2003) Lack of BRAF mutations in uveal melanoma. Cancer Res 63(18):5712–5715

    CAS  PubMed  Google Scholar 

  13. Cohen Y, Goldenberg-Cohen N, Parrella P, Chowers I, Merbs SL, Pe'er J et al (2003) Lack of BRAF mutation in primary uveal melanoma. Invest Ophthalmol Vis Sci 44(7):2876–2878

    Article  PubMed  Google Scholar 

  14. Edmunds SC, Cree IA, Di Nicolantonio F, Hungerford JL, Hurren JS, Kelsell DP (2003) Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br J Cancer 88(9):1403–1405, PMCID: 2741050

    Article  CAS  PubMed  Google Scholar 

  15. Maat W, Kilic E, Luyten GP, de Klein A, Jager MJ, Gruis NA et al (2008) Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma. Invest Ophthalmol Vis Sci 49(1):23–27

    Article  PubMed  Google Scholar 

  16. Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24(26):4340–4346

    Article  CAS  PubMed  Google Scholar 

  17. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J et al (2008) KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 14(21):6821–6828

    Article  CAS  PubMed  Google Scholar 

  18. Besmer P, Murphy JE, George PC, Qiu FH, Bergold PJ, Lederman L et al (1986) A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 320(6061):415–421

    Article  CAS  PubMed  Google Scholar 

  19. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ et al (1987) Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6(11):3341–3351, PMCID: 553789

    CAS  PubMed  Google Scholar 

  20. Woodman SE, Davies MA (2010) Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 80(5):568–574

    Article  CAS  PubMed  Google Scholar 

  21. Huang EJ, Nocka KH, Buck J, Besmer P (1992) Differential expression and processing of two cell associated forms of the kit-ligand: KL-1 and KL-2. Mol Biol Cell 3(3):349–362, PMCID: 275535

    Article  CAS  PubMed  Google Scholar 

  22. Ronnstrand L (2004) Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci 61(19–20):2535–2548

    Article  CAS  PubMed  Google Scholar 

  23. Miyazawa K, Williams DA, Gotoh A, Nishimaki J, Broxmeyer HE, Toyama K (1995) Membrane-bound steel factor induces more persistent tyrosine kinase activation and longer life span of c-kit gene-encoded protein than its soluble form. Blood 85(3):641–649

    CAS  PubMed  Google Scholar 

  24. Russell ES (1979) Hereditary anemias of the mouse: a review for geneticists. Adv Genet 20:357–459

    Article  CAS  PubMed  Google Scholar 

  25. Vincent S, Segretain D, Nishikawa S, Nishikawa SI, Sage J, Cuzin F et al (1998) Stage-specific expression of the Kit receptor and its ligand (KL) during male gametogenesis in the mouse: a Kit-KL interaction critical for meiosis. Development 125(22):4585–4593

    CAS  PubMed  Google Scholar 

  26. Tian Q, Frierson HF Jr, Krystal GW, Moskaluk CA (1999) Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 154(6):1643–1647, PMCID: 1876773

    Article  CAS  PubMed  Google Scholar 

  27. Okayama Y, Kawakami T (2006) Development, migration, and survival of mast cells. Immunol Res 34(2):97–115, PMCID: 1490026

    Article  CAS  PubMed  Google Scholar 

  28. Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB, Bernstein A (1995) W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 373(6512):347–349

    Article  CAS  PubMed  Google Scholar 

  29. Phung B, Sun J, Schepsky A, Steingrimsson E, Ronnstrand L (2011) C-KIT signaling depends on microphthalmia-associated transcription factor for effects on cell proliferation. PLoS One 6(8):e24064, PMCID: 3161112

    Article  CAS  PubMed  Google Scholar 

  30. Hou L, Pavan WJ (2008) Transcriptional and signaling regulation in neural crest stem cell-derived melanocyte development: do all roads lead to Mitf? Cell Res 18(12):1163–1176

    Article  CAS  PubMed  Google Scholar 

  31. Cable J, Jackson IJ, Steel KP (1995) Mutations at the W locus affect survival of neural crest-derived melanocytes in the mouse. Mech Dev 50(2–3):139–150

    Article  CAS  PubMed  Google Scholar 

  32. Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A (1988) The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 335(6185):88–89

    Article  CAS  PubMed  Google Scholar 

  33. Spritz RA, Giebel LB, Holmes SA (1992) Dominant negative and loss of function mutations of the c-kit (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism. Am J Hum Genet 50(2):261–269, PMCID: 1682440

    CAS  PubMed  Google Scholar 

  34. Geissler EN, Ryan MA, Housman DE (1988) The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 55(1):185–192

    Article  CAS  PubMed  Google Scholar 

  35. Alexeev V, Yoon K (2006) Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol 126(5):1102–1110

    Article  CAS  PubMed  Google Scholar 

  36. Hachiya A, Sriwiriyanont P, Kobayashi T, Nagasawa A, Yoshida H, Ohuchi A et al (2009) Stem cell factor-KIT signalling plays a pivotal role in regulating pigmentation in mammalian hair. J Pathol 218(1):30–39

    Article  CAS  PubMed  Google Scholar 

  37. Wang ZQ, Si L, Tang Q, Lin D, Fu Z, Zhang J et al (2009) Gain-of-function mutation of KIT ligand on melanin synthesis causes familial progressive hyperpigmentation. Am J Hum Genet 84(5):672–677, PMCID: 2680999

    Article  CAS  PubMed  Google Scholar 

  38. Huang S, Luca M, Gutman M, McConkey DJ, Langley KE, Lyman SD et al (1996) Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene 13(11):2339–2347

    CAS  PubMed  Google Scholar 

  39. Natali PG, Nicotra MR, Winkler AB, Cavaliere R, Bigotti A, Ullrich A (1992) Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer 52(2):197–201

    Article  CAS  PubMed  Google Scholar 

  40. Montone KT, van Belle P, Elenitsas R, Elder DE (1997) Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol 10(9):939–944

    CAS  PubMed  Google Scholar 

  41. Lassam N, Bickford S (1992) Loss of c-kit expression in cultured melanoma cells. Oncogene 7(1):51–56

    CAS  PubMed  Google Scholar 

  42. Shen SS, Zhang PS, Eton O, Prieto VG (2003) Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J Cutan Pathol 30(9):539–547

    Article  PubMed  Google Scholar 

  43. Ugurel S, Hildenbrand R, Zimpfer A, La Rosee P, Paschka P, Sucker A et al (2005) Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 92(8):1398–1405, PMCID: 2362005

    Article  CAS  PubMed  Google Scholar 

  44. Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F et al (2006) Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106(9):2005–2011

    Article  CAS  PubMed  Google Scholar 

  45. Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH et al (2008) Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 99(5):734–740, PMCID: 2528157

    Article  CAS  PubMed  Google Scholar 

  46. Rubin BP, Heinrich MC, Corless CL (2007) Gastrointestinal stromal tumour. Lancet 369(9574):1731–1741

    Article  CAS  PubMed  Google Scholar 

  47. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364(9440):1127–1134

    Article  CAS  PubMed  Google Scholar 

  48. Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D (1998) Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 58(10):2170–2175

    CAS  PubMed  Google Scholar 

  49. Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S et al (2004) Prevalence of KIT expression in human tumors. J Clin Oncol 22(22):4514–4522

    Article  CAS  PubMed  Google Scholar 

  50. Willmore C, Holden JA, Zhou L, Tripp S, Wittwer CT, Layfield LJ (2004) Detection of c-kit-activating mutations in gastrointestinal stromal tumors by high-resolution amplicon melting analysis. Am J Clin Pathol 122(2):206–216

    Article  CAS  PubMed  Google Scholar 

  51. Willmore-Payne C, Holden JA, Hirschowitz S, Layfield LJ (2006) BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Hum Pathol 37(5):520–527

    Article  CAS  PubMed  Google Scholar 

  52. Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP et al (2007) L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 121(2):257–264

    Article  CAS  PubMed  Google Scholar 

  53. Rivera RS, Nagatsuka H, Gunduz M, Cengiz B, Gunduz E, Siar CH et al (2008) C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 452(1):27–32

    Article  CAS  PubMed  Google Scholar 

  54. Satzger I, Schaefer T, Kuettler U, Broecker V, Voelker B, Ostertag H et al (2008) Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer 99(12):2065–2069, PMCID: 2607233

    Article  CAS  PubMed  Google Scholar 

  55. Ashida A, Takata M, Murata H, Kido K, Saida T (2009) Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer 124(4):862–868

    Article  CAS  PubMed  Google Scholar 

  56. Torres-Cabala CA, Wang WL, Trent J, Yang D, Chen S, Galbincea J et al (2009) Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 22(11):1446–1456

    Article  CAS  PubMed  Google Scholar 

  57. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J et al (2011) KIT as a therapeutic target in metastatic melanoma. JAMA 305(22):2327–2334

    Article  CAS  PubMed  Google Scholar 

  58. Lennartsson J, Blume-Jensen P, Hermanson M, Ponten E, Carlberg M, Ronnstrand L (1999) Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction. Oncogene 18(40):5546–5553

    Article  CAS  PubMed  Google Scholar 

  59. Corless CL, Heinrich MC (2008) Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 3:557–586

    Article  CAS  PubMed  Google Scholar 

  60. Kong Y, Si L, Zhu Y, Xu X, Corless CL, Flaherty KT et al (2011) Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 17(7):1684–1691

    Article  CAS  PubMed  Google Scholar 

  61. Yun J, Lee J, Jang J, Lee EJ, Jang KT, Kim JH et al (2011) KIT amplification and gene mutations in acral/mucosal melanoma in Korea. APMIS 119(6):330–335

    Article  CAS  PubMed  Google Scholar 

  62. Handolias D, Salemi R, Murray W, Tan A, Liu W, Viros A et al (2010) Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res 23(2):210–215

    Article  CAS  PubMed  Google Scholar 

  63. Monsel G, Ortonne N, Bagot M, Bensussan A, Dumaz N (2010) c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes. Oncogene 29(2):227–236

    Article  CAS  PubMed  Google Scholar 

  64. Jiang X, Zhou J, Yuen NK, Corless CL, Heinrich MC, Fletcher JA et al (2008) Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 14(23):7726–7732

    Article  CAS  PubMed  Google Scholar 

  65. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM et al (2009) Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 8(8):2079–2085

    Article  CAS  PubMed  Google Scholar 

  66. Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A et al (2008) Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 26(12):2046–2051

    Article  CAS  PubMed  Google Scholar 

  67. Satzger I, Kuttler U, Volker B, Schenck F, Kapp A, Gutzmer R (2010) Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy–case report and review of the literature. Dermatology 220(1):77–81

    Article  PubMed  Google Scholar 

  68. Lutzky J, Bauer J, Bastian BC (2008) Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 21(4):492–493

    Article  PubMed  Google Scholar 

  69. Fisher DE, Barnhill R, Hodi FS, Herlyn M, Merlino G, Medrano E et al (2010) Melanoma from bench to bedside: meeting report from the 6th international melanoma congress. Pigment Cell Melanoma Res 23:14–26

    Article  CAS  PubMed  Google Scholar 

  70. Quintas-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P (2008) Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 5(12):737–740

    Article  CAS  PubMed  Google Scholar 

  71. Zhu Y, Si L, Kong Y, Chi Z, Yuan X, Cui C, et al. (2009) Response to sunitinib in Chinese KIT – mutated metastatic mucosal melanoma. J Clin Oncol 27(abstract):e20017

    Google Scholar 

  72. Minor DR, Kashani-Sabet M, Garrido M, O'Day SJ, Hamid O, Bastian BC (2012) Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res 18(5):1457–1463

    Article  CAS  PubMed  Google Scholar 

  73. Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB et al (2011) A phase 2 trial of dasatinib in advanced melanoma. Cancer 117(10):2202–2208

    Article  CAS  PubMed  Google Scholar 

  74. Cho JH, Kim KM, Kwon M, Kim JH, Lee J (2011) Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs 30(5):2008–2014

    Article  PubMed  Google Scholar 

  75. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ et al (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29(10):1239–1246

    Article  PubMed  Google Scholar 

  76. Guo T, Hajdu M, Agaram NP, Shinoda H, Veach D, Clarkson BD et al (2009) Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res 15(22):6862–6870, PMCID: 2783687

    Article  CAS  PubMed  Google Scholar 

  77. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ et al (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24(29):4764–4774

    Article  CAS  PubMed  Google Scholar 

  78. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21(23):4342–4349

    Article  CAS  PubMed  Google Scholar 

  79. Lasota J, Corless CL, Heinrich MC, Debiec-Rychter M, Sciot R, Wardelmann E et al (2008) Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol 21(4):476–484

    Article  CAS  PubMed  Google Scholar 

  80. Fletcher JA, Rubin BP (2007) KIT mutations in GIST. Curr Opin Genet Dev 17(1):3–7

    Article  CAS  PubMed  Google Scholar 

  81. Si L, Xu X, Kong Y, Flaherty KT, Chi Z, Cui C et al (2012) Major response to everolimus in melanoma with acquired imatinib resistance. J Clin Oncol 30(4):e37–e40

    Article  CAS  PubMed  Google Scholar 

  82. Handolias D, Hamilton AL, Salemi R, Tan A, Moodie K, Kerr L et al (2010) Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer 102(8):1219–1223, PMCID: 2856012

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Melanoma/Sarcoma Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Richard D. Carvajal

  2. The Angeles Clinic and Research Institute, Los Angeles, CA, USA

    Omid Hamid

  3. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Cristina R. Antonescu

Authors
  1. Richard D. Carvajal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Omid Hamid
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cristina R. Antonescu
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cancer Diagnosis Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

    Magdalena Thurin

  2. Sidra Medical and Research Center,Qatar Foundation, Doha, Qatar

    Francesco M. Marincola

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media, New York

About this protocol

Cite this protocol

Carvajal, R.D., Hamid, O., Antonescu, C.R. (2014). Selecting Patients for KIT Inhibition in Melanoma. In: Thurin, M., Marincola, F. (eds) Molecular Diagnostics for Melanoma. Methods in Molecular Biology, vol 1102. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-727-3_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-727-3_9

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-726-6

  • Online ISBN: 978-1-62703-727-3

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation